mRNAワクチン市場レポート：2026-2036
mRNA Vaccines Market Report 2026-2036
説明
Visiongainは新たなレポートを発表しました。 mRNAワクチン市場レポート 2026-2036 、世界のmRNAワクチン市場について、市場規模、成長要因、競合状況、および主要なワクチン種類、用途、エンド... もっと見る
※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。
|
サマリー
説明
Visiongainは新たなレポートを発表しました。mRNAワクチン市場レポート 2026-2036、世界のmRNAワクチン市場について、市場規模、成長要因、競合状況、および主要なワクチン種類、用途、エンドユーザーごとの売上予測を含む包括的な分析を提供しています。
世界のmRNAワクチン市場は、2026年の97億米ドルから、2031年には168億米ドル、2036年には347億米ドルへと拡大すると見込まれており、予測期間中の年平均成長率（CAGR）は13.6％となる見通しです。
年間成長率は、2026年に7.9％、2031年に14.5％、2036年に16.2％と予測されており、これはmRNAプラットフォーム開発への投資の加速、感染症以外の治療分野への応用拡大、および腫瘍学や自己免疫疾患の適応症における採用拡大を反映したものである。
この成長は、mRNA送達システムの工学における継続的な進歩、自己増幅型mRNA技術の採用拡大、そしてパンデミック対策や標的治療プログラムにおける迅速なワクチン開発に向けたmRNAプラットフォームへの依存度の高まりによって牽引されています。
市場拡大を牽引する技術革新
脂質ナノ粒子工学およびmRNA送達システムの急速な進歩により、世界のmRNAワクチン市場の競争環境は一変しつつある。 脂質頭部、疎水性尾部、および脂質とmRNAの比率の最適化を含む、イオン化可能な脂質構造の改良により、細胞質への送達、エンドソームからの脱出、およびトランスフェクション効率が向上すると同時に、意図しない炎症反応が抑制されている。
また、開発の取り組みは、従来の脂質ナノ粒子にとどまらず、カプセル化性能を損なうことなく生分解性を向上させ、脂質に起因する毒性を低減するよう設計された、有機系および高分子系の担体へと広がっています。粒子径分布、表面特性、および添加剤の選定に焦点を当てた製剤工学により、製造およびコールドチェーン流通の全過程において、mRNAの安定性と耐久性が強化されています。
同時に、AIを活用した創薬プラットフォームと自己増幅型mRNA技術の統合により、ワクチンや治療薬の開発ペースが加速しており、各組織は開発期間の短縮や、対象となる適応症のパイプラインの拡大を図ることが可能になっています。
貿易、政策、およびサプライチェーンの動向
-
mRNAワクチン市場は、世界的な貿易動向、規制の枠組み、そして地政学的な情勢の変化の影響をますます強く受けている。
-
この市場は、ヌクレオチド、キャッピング試薬、酵素、脂質、シングルユースシステム、分析機器、コールドチェーン用部品など、世界中から調達される特殊な原材料に大きく依存しており、GMPグレードの原材料をめぐる関税、輸出規制、およびサプライチェーン上の制約の影響を受けやすい状況にある。
-
米国によるバイオ製造用原材料や設備の輸入に対する関税は、調達コストを押し上げ、リードタイムを長期化させ、国境を越えた供給ネットワークを持つCDMOやワクチン開発企業に圧力をかけている。
-
ワクチンや生物製剤などの規制対象分野においては、データ保護の枠組み、製造基準、および承認プロセスへの準拠が、主要地域における市場参入、価格設定、および業務遂行に引き続き大きな影響を与え続けている。
商業的影響
-
コストおよび価格面での圧力：原材料費、製造コスト、コンプライアンス関連コストの上昇が、CDMOの利益率に影響を及ぼしており、mRNAワクチン開発企業のプログラム全体の予算を増大させている
-
サプライチェーンの変容：企業は、関税リスクを軽減し、サプライチェーンの回復力を高めるため、米国での製造投資、デュアルソーシング、および地域ごとの充填・仕上げ生産能力の拡充を加速させている
-
規制の影響：主要地域における市場参入や開発スケジュールは、変化し続ける承認枠組み、パンデミック対策の義務付け、および公共調達の要件によって左右される
-
競争上の優位性：垂直統合型の製造能力と確立された規制対応実績を持つ企業は、長期的な市場成長を捉える上でより有利な立場にある
企業情報
mRNAワクチン市場は、定評のある大手バイオ医薬品企業、mRNAプラットフォーム開発の専門企業、そして新興の治療薬開発企業が混在しており、各社は科学的イノベーション、製造規模、規制対応能力の面で競い合っている。
BioNTech SE、Moderna、Pfizer、Sanofi などの主要企業は、プラットフォームの開発、戦略的提携、およびがん、自己免疫疾患、個別化医療の適応症分野への進出を通じて、その地位を強化している。
競争は、ますます以下の要素によって特徴づけられるようになっている：
-
mRNAプラットフォーム技術の能力と送達システムの革新
-
規制および製造規模における実績
-
感染症、腫瘍学、自己免疫疾患の各領域にわたる幅広いパイプライン
-
大規模な迅速な開発とグローバルな展開を支援する能力
一方で、自己増幅型mRNA技術、AIを活用した設計、あるいは標的を絞った治療への注力といった点で差別化を図っている新規参入企業や専門の開発企業が、勢いを増しつつある。
本レポートでは、競争上の位置づけがどのように変化しているかを分析し、価値がどこで創出されているか、また予測期間において戦略がどのように変化すると予想されるかを明らかにする。
主な疑問への回答
-
2036年までのmRNAワクチン市場の規模はどの程度になると予測されていますか？
-
どのセグメントや地域が成長を牽引するのでしょうか？
-
デリバリーシステムや自己増幅型mRNA技術の進歩は、市場の進化にどのような影響を与えるのでしょうか？
-
貿易、政策、サプライチェーンの動向は、製造コストや市場アクセスにどのような影響を与えるのでしょうか？
-
主要企業はどこか、またそれらの地位は今後どのように変化していくのか？
レポートの範囲とデータの対象範囲
-
世界のmRNAワクチン市場分析
-
2036年までの売上高予測
-
ワクチンの種類、用途、およびエンドユーザーにわたるセグメントレベルのモデリング
-
地域別および全国市場の予測
-
主要企業11社に関する競合情報
定量的な予測と定性的な戦略分析の両方を含み、技術、競争、政策、サプライチェーンの動向を網羅しています。
セグメンテーション
タイプ別
-
自己増幅型mRNAワクチン
-
従来の非増幅型mRNAワクチン
用途別
エンドユーザー別
対象地域
北米
欧州
-
ドイツ
-
イギリス
-
フランス
-
イタリア
-
スペイン
-
その他の欧州地域
アジア太平洋地域
-
日本
-
中国
-
インド
-
オーストラリア
-
韓国
-
その他のアジア太平洋地域
ラテンアメリカ
MEA
企業情報 取材範囲
本レポートには、以下を含む11社の主要企業の詳細なプロフィールが掲載されています：
-
AIM Vaccine
-
Arcturus Therapeutics, Inc.
-
BioNTech SE
-
DAIICHI SANKYO COMPANY, LIMITED
-
etherna
-
Ethris
-
GSK plc
-
Moderna, Inc.
-
Pfizer Inc.
-
Sanofi
-
Strand Therapeutics
各プロフィールには以下の内容が含まれています：
-
事業概要
-
財務および市場における位置づけ
-
製品および技術力
-
戦略的展望
オーダーメイド型インテリジェンス＆カスタマイズ
また、Visiongainでは、お客様それぞれの具体的なご要望に合わせた、オーダーメイド型の情報提供およびアドバイザリー支援も行っています。
これには以下が含まれます：
-
カスタマイズされた市場セグメンテーションと予測
-
競合他社とのベンチマークおよび戦略分析
-
政策および規制の影響評価
-
サプライチェーンおよび調達インテリジェンス
-
関税や地政学的リスクを含むシナリオ・モデリング
この市場情報が重要な理由
-
mRNAワクチン市場は、プラットフォーム技術の進歩、治療用途の拡大、そして製造およびサプライチェーン戦略の転換を背景に、急速に進化しています。
-
こうした力学を理解している組織は、成長の機会を捉え、リスクを管理し、競争上の優位性を強化する上で、より有利な立場に立つことができるでしょう。
-
「mRNAワクチン市場レポート 2026～2036」をご購入いただくと、完全なデータセット、予測、および競合分析をご覧いただけます。
ページTOPに戻る
目次
1 レポートの概要
1.1 本調査の目的
1.2 mRNAワクチン市場の概要
1.3 本レポートで提供される内容
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問：
1.6 本レポートの対象読者
1.7 調査方法
1.7.1 市場の定義
1.7.2 市場評価および予測の方法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 二次調査
1.8 よくある質問（FAQ）
1.9 関連するVisiongainレポート
1.10 Visiongainについて
2 概要
3 市場の概要
3.1 主な調査結果
3.2 市場の動向
3.3 影響分析
3.3.1 市場を牽引する要因
3.3.1.1 mRNAワクチン開発に向けた研究開発投資の拡大
3.3.1.2 送達システムの技術的進歩
3.3.1.3 ワクチン接種を促進するための政府主導の取り組みおよび政策の増加
3.3.2 市場の抑制要因
3.3.2.1 mRNAワクチンに伴う高価格
3.3.2.2 mRNAワクチンの承認に関する厳格な規制
3.3.3 市場の機会
3.3.3.1 mRNAワクチンの用途拡大
3.3.3.2 現地化されたmRNA製造および技術移転ハブの成長
3.3.3.3 自己増幅型mRNA（saRNA）プラットフォームの進歩
3.4 米国の関税：世界のmRNAワクチン市場への影響は？
3.4.1 概要
3.4.2 V字型回復シナリオ
3.4.3 なぜV字型回復なのか？
3.4.3.1 関税による影響
3.4.3.2 市場の動向と需要の回復
3.4.3.3 政策および資金支援
3.4.3.4 回復までの期間
3.4.4 U字型回復シナリオ
3.4.4.1 なぜU字型回復なのか？
3.4.4.2 関税の影響
3.4.4.3 市場の動向と需要の回復
3.4.4.4 政策および資金面での支援
3.4.4.5 回復までの期間
3.4.5 L字型回復シナリオ
3.4.5.1 なぜL字型回復なのか？
3.4.5.2 関税の影響
3.4.5.3 市場の動向と需要の回復
3.4.5.4 政策および資金面での支援
3.4.5.5 回復までの期間
3.4.6 顧客は、短期（2026～2031年）および長期（2026～2036年）の計画において、どのような戦略的考慮事項を織り込むべきか？
3.4.7 米中貿易戦争がmRNAワクチン市場に与える影響
3.4.8 最も影響を受ける国々は、これらの政策変更によってどのようなプラスおよびマイナスの影響を受ける可能性があるか？
3.5 ポーターの5つの力分析
3.5.1 供給者の交渉力 ー 中～高
3.5.2 買い手の交渉力 ー 中
3.5.3 競合の激しさ ー 高
3.5.4 代替品の脅威 ー 中
3.5.5 新規参入の脅威 ー 低
3.6 PEST分析
4. mRNAワクチン市場分析：タイプ別
4.1 主な調査結果
4.2 タイプ別セグメント：市場魅力度指数
4.3 タイプ別のmRNAワクチン市場規模の推計および予測
4.4 自己増幅型mRNAワクチン
4.4.1 地域別市場予測、2026年～2036年（百万米ドル、年平均成長率（AGR）％）
4.4.2 地域別市場シェア、2026年および2036年（％）
4.5 従来の非増幅型mRNAワクチン
4.5.1 地域別市場予測、2026年～2036年（百万米ドル、年平均成長率（AGR）％）
4.5.2 地域別市場シェア、2026年および2036年（％）
5. mRNAワクチン市場分析：用途別
5.1 主な調査結果
5.2 用途別セグメント：市場魅力度指数
5.3 用途別のmRNAワクチン市場規模の推計および予測
5.4 がん
5.4.1 地域別市場予測、2026年～2036年（百万米ドル、年平均成長率（AGR）％）
5.4.2 地域別市場シェア、2026年および2036年（％）
5.5 感染症
5.5.1 地域別市場予測、2026年～2036年（百万米ドル、年平均成長率（AGR）％）
5.5.2 地域別市場シェア、2026年および2036年（％）
5.6 自己免疫疾患
5.6.1 地域別市場予測、2026年～2036年（百万米ドル、年平均成長率（AGR）％）
5.6.2 地域別市場シェア、2026年および2036年（％）
5.7 その他
5.7.1 地域別市場予測、2026年～2036年（百万米ドル、年平均成長率％）
5.7.2 地域別市場シェア、2026年および2036年（％）
6. mRNAワクチン市場分析：エンドユーザー別
6.1 主な調査結果
6.2 エンドユーザー別セグメント：市場魅力度指数
6.3 エンドユーザー別のmRNAワクチン市場規模の推計および予測
6.4 病院および診療所
6.4.1 地域別市場予測、2026年～2036年（百万米ドル、年平均成長率（AGR）％）
6.4.2 地域別市場シェア、2026年および2036年（％）
6.5 研究機関
6.5.1 地域別市場予測、2026年～2036年（百万米ドル、年平均成長率％）
6.5.2 地域別市場シェア、2026年および2036年（％）
6.6 その他
6.6.1 地域別市場予測、2026年～2036年（百万米ドル、年平均成長率％）
6.6.2 地域別市場シェア、2026年および2036年（％）
mRNAワクチン市場分析：地域別
7.1 主な調査結果
7.2 地域別市場規模の推計と予測
8 北米のmRNAワクチン市場分析
8.1 主な調査結果
8.2 北米mRNAワクチン市場の魅力度指数
8.3 北米mRNAワクチン市場：国別、2026年、2031年、2036年（百万米ドル）
8.4 北米mRNAワクチン市場規模推定と予測：国別
8.5 北米mRNAワクチン市場規模推定と予測：種類別
8.6 北米mRNAワクチン市場規模推定と予測：用途別
8.7 北米mRNAワクチン市場規模推定と予測：エンドユーザー別
8.8 米国mRNAワクチン市場の分析
8.9 カナダmRNAワクチン市場の分析
9 欧州のmRNAワクチン市場分析
9.1 主な調査結果
9.2 欧州mRNAワクチン市場の魅力度指数
9.3 欧州mRNAワクチン市場：国別、2026年、2031年、2036年（百万米ドル）
9.4 欧州mRNAワクチン市場規模推定と予測：国別
9.5 欧州mRNAワクチン市場規模推定と予測：種類別
9.6 欧州mRNAワクチン市場規模推定と予測：用途別
9.7 欧州mRNAワクチン市場規模推定と予測：エンドユーザー別
9.8 ドイツのmRNAワクチン市場分析
9.9 英国のmRNAワクチン市場分析
9.10 フランスのmRNAワクチン市場分析
9.11 イタリアのmRNAワクチン市場分析
9.12 スペインのmRNAワクチン市場分析
9.13 その他の欧州地域のmRNAワクチン市場分析
10 アジア太平洋地域のmRNAワクチン市場分析
10.1 主な調査結果
10.2 アジア太平洋地域のmRNAワクチン市場の魅力度指数
10.3 アジア太平洋地域のmRNAワクチン市場：国別、2026年、2031年、2036年（百万米ドル）
10.4 アジア太平洋地域のmRNAワクチン市場規模推定と予測：国別
10.5 アジア太平洋地域のmRNAワクチン市場規模推定と予測：タイプ別
10.6 アジア太平洋地域のmRNAワクチン市場規模推定と予測：用途別
10.7 アジア太平洋地域のmRNAワクチン市場規模推定と予測：エンドユーザー別
10.8 日本のmRNAワクチン市場分析
10.9 中国のmRNAワクチン市場分析
10.10 インドのmRNAワクチン市場分析
10.11 オーストラリアのmRNAワクチン市場分析
10.12 その他のアジア太平洋地域mRNAワクチン市場分析
11 ラテンアメリカのmRNAワクチン市場分析
11.1 主な調査結果
11.2 ラテンアメリカのmRNAワクチン市場の魅力度指数
11.3 ラテンアメリカのmRNAワクチン市場：国別、2026年、2031年、2036年（百万米ドル）
11.4 ラテンアメリカのmRNAワクチン市場規模推定と予測：国別
11.5 ラテンアメリカのmRNAワクチン市場規模推定と予測：タイプ別
11.6 ラテンアメリカのmRNAワクチン市場規模推定と予測：用途別
11.7 ラテンアメリカのmRNAワクチン市場規模推定と予測：エンドユーザー別
11.8 ブラジルmRNAワクチン市場分析
11.9 メキシコmRNAワクチン市場分析
11.10 その他のラテンアメリカmRNAワクチン市場分析
12 MEAのmRNAワクチン市場の分析
12.1 主な調査結果
12.2 MEAのmRNAワクチン市場の魅力度指数
12.3 MEAのmRNAワクチン市場：国別、2026年、2031年、2036年（百万米ドル）
12.4 MEAのmRNAワクチン市場規模の推定と予測：国別
12.5 MEAのmRNAワクチン市場規模の推定と予測：タイプ別
12.6 MEAのmRNAワクチン市場規模の推定と予測：用途別
12.7 MEAのmRNAワクチン市場規模の推定と予測：エンドユーザー別
12.8 GCC地域のmRNAワクチン市場分析
12.9 南アフリカにおけるmRNAワクチン市場分析
12.10 その他のMEA地域のmRNAワクチン市場分析
13 主要企業の概要
13.1 ファイザー社
13.1.1 企業概要
13.1.2 会社概要
13.1.3 財務分析
13.1.3.1 純売上高（2021年～2025年）
13.1.3.2 研究開発費（R&D）、2021年～2025年
13.1.3.3 地域別市場シェア、2025年
13.1.3.4 事業セグメント別市場シェア、2025年
13.1.4 製品ベンチマーク
13.1.5 戦略的展望
13.2 モデルナ社（Moderna, Inc.）
13.2.1 企業概要
13.2.2 会社概要
13.2.3 財務分析
13.2.3.1 純売上高（2021年～2025年）
13.2.3.2 研究開発費（2021年～2025年）
13.2.3.3 地域別市場シェア（2025年）
13.2.3.4 事業セグメント別市場シェア（2025年）
13.2.4 製品ベンチマーク
13.2.5 戦略的展望
13.3 BioNTech SE
13.3.1 企業概要
13.3.2 会社概要
13.3.3 財務分析
13.3.3.1 純売上高（2021年～2025年）
13.3.3.2 研究開発費（2021年～2025年）
13.3.3.3 地域別市場シェア（2025年）
13.3.3.4 事業セグメント別市場シェア（2025年）
13.3.4 製品ベンチマーキング
13.3.5 戦略的展望
13.4 GSK plc
13.4.1 企業概要
13.4.2 会社概要
13.4.3 財務分析
13.4.3.1 純売上高、2021-2025年
13.4.3.2 研究開発費（2021年～2025年）
13.4.3.3 地域別市場シェア（2025年）
13.4.3.4 事業セグメント別市場シェア（2025年）
13.4.4 製品ベンチマーク
13.4.5 戦略的展望
13.5 第一三共株式会社
13.5.1 企業概要
13.5.2 会社概要
13.5.3 財務分析
13.5.3.1 純売上高（2021年～2025年）
13.5.3.2 研究開発費（2021年～2025年）
13.5.3.3 地域別市場シェア（2025年）
13.5.4 製品ベンチマーキング
13.6 エスリス
13.6.1 企業概要
13.6.2 会社概要
13.6.3 製品ベンチマーク
13.6.4 戦略的展望
13.7 AIM Vaccine
13.7.1 企業概要
13.7.2 会社概要
13.7.3 財務分析
13.7.3.1 純売上高（2022年～2024年）
13.7.4 製品ベンチマーク
13.7.5 戦略的展望
13.8 Arcturus Therapeutics, Inc.
13.8.1 企業概要
13.8.2 会社概要
13.8.3 製品ベンチマーク
13.8.4 戦略的展望
13.9 サノフィ
13.9.1 企業概要
13.9.2 会社概要
13.9.3 財務分析
13.9.3.1 純売上高（2021年～2025年）
13.9.3.2 研究開発費（2021年～2025年）
13.9.3.3 地域別市場シェア（2025年）
13.9.3.4 事業セグメント別市場シェア（2025年）
13.9.4 製品ベンチマーキング
13.9.5 戦略的展望
14 結論と提言
14.1 Visiongainによる総括
14.2 市場関係者への提言
ページTOPに戻る
図表リスト
List of Tables
Table 1 mRNA Vaccines Market Snapshot, 2026 & 2036 (US$ million, CAGR %)
Table 2 mRNA Vaccines Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%): “V” Shaped Recovery
Table 3 mRNA Vaccines Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%): “U” Shaped Recovery
Table 4 mRNA Vaccines Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%): “L” Shaped Recovery
Table 5 mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 6 Self-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 7 Conventional Non-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 8 mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 9 Cancer Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 10 Infectious Diseases Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 11 Autoimmune DiseasesSegment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 12 Other Applications Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 13 mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 14 Hospitals and Clinics Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 15 Research Organisations Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 16 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 17 mRNA Vaccines Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 18 North America mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 19 North America mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 20 North America mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 21 North America mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 22 U.S. mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 23 Canada mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 24 Europe mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 25 Europe mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 26 Europe mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 27 Europe mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 28 Germany mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 29 UK mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 30 France mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 31 Italy mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 32 Spain mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 33 Rest of Europe mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 34 Asia Pacific mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 35 Asia Pacific mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 36 Asia Pacific mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 37 Asia Pacific mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 38 Japan mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 39 China mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 40 India mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 41 Australia mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 42 Rest of Asia Pacific mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 43 Latin America mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 44 Latin America mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 45 Latin America mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 46 Latin America mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 47 Brazil mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 48 Mexico mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 49 Rest of Latin America mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 50 MEA mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 51 MEA mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 52 MEA mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 53 MEA mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 54 GCC mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 55 South Africa mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 56 Rest of MEA mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 57 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 58 Pfizer Inc.: Product Benchmarking
Table 59 Pfizer Inc.: Strategic Outlook
Table 60 Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 61 Moderna, Inc.: Product Benchmarking
Table 62 Moderna, Inc.: Strategic Outlook
Table 63 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 64 BioNTech SE: Product Benchmarking
Table 65 BioNTech SE: Strategic Outlook
Table 66 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 67 GSK plc: Product Benchmarking
Table 68 GSK plc: Strategic Outlook
Table 69 DAIICHI SANKYO COMPANY, LIMITED: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 DAIICHI SANKYO COMPANY, LIMITED: Product Benchmarking
Table 71 Ethris: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 72 Ethris: Product Benchmarking
Table 73 Ethris: Strategic Outlook
Table 74 AIM Vaccine: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 75 AIM Vaccine: Product Benchmarking
Table 76 AIM Vaccine: Strategic Outlook
Table 77 Arcturus Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 78 Arcturus Therapeutics, Inc.: Product Benchmarking
Table 79 Arcturus Therapeutics, Inc.: Strategic Outlook
Table 80 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Sanofi: Product Benchmarking
Table 82 Sanofi: Strategic Outlook
List of Figures
Figure 1 mRNA Vaccines Market Segmentation
Figure 2 mRNA Vaccines Market by Type: Market Attractiveness Index
Figure 3 mRNA Vaccines Market by Application: Market Attractiveness Index
Figure 4 mRNA Vaccines Market by End-users: Market Attractiveness Index
Figure 5 mRNA Vaccines Market Attractiveness Index by Region
Figure 6 mRNA Vaccines Market: Market Dynamics
Figure 7 mRNA Vaccines Market: Impact Analysis
Figure 8 mRNA Vaccines Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 9 mRNA Vaccines Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 10 mRNA Vaccines Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 11 Short Term & Long Term Planning
Figure 12 Impact of U.S. and China Trade War
Figure 13 Most Impacted Countries
Figure 14 mRNA Vaccines Market: Porter’s Five Forces Analysis
Figure 15 mRNA Vaccines Market: PEST Analysis
Figure 16 mRNA Vaccines Market Attractiveness Index by Type
Figure 17 mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
Figure 18 mRNA Vaccines Market Share Forecast by Type, 2026, 2031, 2036 (%)
Figure 19 Self-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 20 Self-amplifying mRNA-based Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 21 Conventional Non-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 22 Conventional Non-amplifying mRNA-based Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 23 mRNA Vaccines Market Attractiveness Index by Type
Figure 24 mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
Figure 25 mRNA Vaccines Market Share Forecast by Application, 2026, 2031, 2036 (%)
Figure 26 Cancer Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 27 Cancer Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 28 Infectious Disease Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 29 Infectious Disease Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 30 Autoimmune Diseases Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 31 Autoimmune Diseases Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 32 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 33 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 34 mRNA Vaccines Market Attractiveness Index by End-users
Figure 35 mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
Figure 36 mRNA Vaccines Market Share Forecast by End-users, 2026, 2031, 2036 (%)
Figure 37 Hospitals and Clinics Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 38 Hospitals and Clinics Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 39 Research Organisations Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 40 Research Organisations Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 41 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 42 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 43 mRNA Vaccines Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
Figure 44 mRNA Vaccines Market Share Forecast by Region 2026, 2031, 2036 (%)
Figure 45 mRNA Vaccines Market by Region, 2026-2036 (US$ Mn)
Figure 46 North America mRNA Vaccines Market Attractiveness Index
Figure 47 North America mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 48 North America mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 49 North America mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
Figure 50 North America mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
Figure 51 North America mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
Figure 52 North America mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
Figure 53 North America mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
Figure 54 North America mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
Figure 55 North America mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 56 U.S. mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 57 Canada mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 58 Europe mRNA Vaccines Market Attractiveness Index
Figure 59 Europe mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 60 Europe mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 61 Europe mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
Figure 62 Europe mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
Figure 63 Europe mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
Figure 64 Europe mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
Figure 65 Europe mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
Figure 66 Europe mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
Figure 67 Europe mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 68 Germany mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 69 UK mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 70 France mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 71 Italy mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 72 Spain mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 73 Rest of Europe mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 74 Asia Pacific mRNA Vaccines Market Attractiveness Index
Figure 75 Asia Pacific mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 76 Asia Pacific mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 77 Asia Pacific mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
Figure 78 Asia Pacific mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
Figure 79 Asia Pacific mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
Figure 80 Asia Pacific mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
Figure 81 Asia Pacific mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
Figure 82 Asia Pacific mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
Figure 83 Asia Pacific mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 84 Japan mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 85 China mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 86 India mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 87 Australia mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 88 Rest of Asia Pacific mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 89 Latin America mRNA Vaccines Market Attractiveness Index
Figure 90 Latin America mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 91 Latin America mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 92 Latin America mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
Figure 93 Latin America mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
Figure 94 Latin America mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
Figure 95 Latin America mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
Figure 96 Latin America mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
Figure 97 Latin America mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
Figure 98 Latin America mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 99 Brazil mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 100 Mexico mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 101 Rest of Latin America mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 102 MEA mRNA Vaccines Market Attractiveness Index
Figure 103 MEA mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 104 MEA mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 105 MEA mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
Figure 106 MEA mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
Figure 107 MEA mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
Figure 108 MEA mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
Figure 109 MEA mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
Figure 110 MEA mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
Figure 111 MEA mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 112 GCC mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 113 South Africa mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 114 Rest of MEA mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 115 Pfizer Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 116 Pfizer Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 117 Pfizer Inc.: Regional Market Shares (%), 2025
Figure 118 Pfizer Inc.: Business Segment Market Shares (%), 2025
Figure 119 Moderna, Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 120 Moderna, Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 121 Moderna, Inc.: Regional Market Shares (%), 2025
Figure 122 Moderna, Inc.: Business Segment Market Shares (%), 2025
Figure 123 BioNTech SE: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 124 BioNTech SE: R&D, 2021-2025 (US$ Million, AGR %)
Figure 125 BioNTech SE: Regional Market Shares (%), 2025
Figure 126 BioNTech SE: Business Segment Market Shares (%), 2025
Figure 127 GSK plc: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 128 GSK plc: R&D, 2021-2025 (US$ Million, AGR %)
Figure 129 GSK plc: Regional Market Shares (%), 2025
Figure 130 GSK plc: Business Segment Market Shares (%), 2025
Figure 131 DAIICHI SANKYO COMPANY, LIMITED: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 132 DAIICHI SANKYO COMPANY, LIMITED: R&D, 2021-2025 (US$ Million, AGR %)
Figure 133 DAIICHI SANKYO COMPANY, LIMITED: Regional Market Shares (%), 2025
Figure 134 AIM Vaccine: Net Revenue, 2022-2024 (US$ Million, AGR %)
Figure 135 Sanofi: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 136 Sanofi: R&D, 2021-2025 (US$ Million, AGR %)
Figure 137 Sanofi: Regional Market Shares (%), 2025
Figure 138 Sanofi: Business Segment Market Shares (%), 2025
ページTOPに戻る
Summary
Description
Visiongain has published a new report, mRNA Vaccines Market Report 2026-2036, providing a comprehensive analysis of the global mRNA vaccines market, including market size, growth drivers, competitive positioning, and revenue forecasts across key vaccine types, applications, and end users.
The global mRNA vaccines market is expected to grow from US$9.7bn in 2026 to US$16.8bn by 2031 and US$34.7bn by 2036, at a CAGR of 13.6% over the forecast period.
Annual growth rates are forecast at 7.9% in 2026, 14.5% in 2031, and 16.2% in 2036, reflecting accelerating investment in mRNA platform development, expanding therapeutic applications beyond infectious disease, and growing adoption across oncology and autoimmune indications.
This growth is driven by continued advances in mRNA delivery system engineering, increasing adoption of self-amplifying mRNA technologies, and growing reliance on mRNA platforms for rapid vaccine development across pandemic preparedness and targeted therapeutic programmes.
Technological Innovation Driving Market Expansion
Rapid advances in lipid nanoparticle engineering and mRNA delivery systems are reshaping the competitive landscape of the global mRNA vaccines market. Refinements to ionisable lipid structures, including optimisation of lipid head groups, hydrophobic tails, and lipid-to-mRNA ratios, are improving cytosolic delivery, endosomal escape, and transfection efficiency while limiting unintended inflammatory responses.
Development efforts are also extending beyond conventional lipid nanoparticles toward organic and polymer-based carriers designed to improve biodegradability and reduce lipid-associated toxicity without compromising encapsulation performance. Formulation engineering focused on particle size distribution, surface characteristics, and excipient selection is strengthening mRNA stability and resilience across manufacturing and cold-chain distribution.
At the same time, the integration of AI-enabled drug discovery platforms and self-amplifying mRNA technologies is accelerating the pace of vaccine and therapeutic development, helping organisations reduce timelines and broaden the pipeline of addressable indications.
Trade, Policy & Supply Chain Dynamics
-
The mRNA vaccines market is increasingly influenced by global trade dynamics, regulatory frameworks, and geopolitical developments.
-
The market depends heavily on specialised globally sourced raw materials including nucleotides, capping reagents, enzymes, lipids, single-use systems, analytical equipment, and cold-chain components, creating exposure to tariffs, export controls, and supply-chain constraints around GMP-grade materials.
-
US trade tariffs on imported biomanufacturing inputs and equipment are increasing procurement costs, lengthening lead times, and placing pressure on CDMOs and vaccine developers with cross-border supply networks.
-
In regulated sectors such as vaccines and biologics, compliance with data protection frameworks, manufacturing standards, and approval processes continues to shape market access, pricing, and operational execution across key regions.
Commercial Impact
-
Cost and pricing pressure: Rising input, manufacturing, and compliance costs are impacting CDMO margins and increasing overall programme budgets for mRNA vaccine developers
-
Supply chain shifts: Companies are accelerating US-based manufacturing investment, dual sourcing, and regional fill-finish capacity to reduce tariff exposure and improve supply-chain resilience
-
Regulatory influence: Market access and development timelines are shaped by evolving approval frameworks, pandemic preparedness mandates, and public procurement requirements across key regions
-
Competitive positioning: Companies with vertically integrated manufacturing capabilities and established regulatory credentials are better positioned to capture long-term market growth
Company Intelligence
The mRNA vaccines market is characterised by a mix of established biopharmaceutical leaders, specialist mRNA platform developers, and emerging therapeutics companies competing across scientific innovation, manufacturing scale, and regulatory capability.
Leading companies including BioNTech SE, Moderna, Pfizer, and Sanofi are strengthening their positions through platform development, strategic partnerships, and expansion into oncology, autoimmune, and personalised medicine indications.
Competition is increasingly defined by:
-
mRNA platform technology capability and delivery system innovation
-
Regulatory and manufacturing scale credentials
-
Pipeline breadth across infectious disease, oncology, and autoimmune applications
-
Ability to support rapid development and global distribution at scale
At the same time, newer entrants and specialist developers are gaining traction where self-amplifying mRNA technologies, AI-enabled design, or targeted therapeutic focus create differentiation.
This report analyses how competitive positioning is evolving, identifying where value is being created and how strategies are expected to shift over the forecast period.
Key Questions Answered
-
What is the projected size of the mRNA vaccines market by 2036?
-
Which segments and regions will drive growth?
-
How will advances in delivery systems and self-amplifying mRNA technologies shape market evolution?
-
How will trade, policy, and supply chain dynamics impact manufacturing costs and market access?
-
Who are the leading companies and how will their positions evolve?
Report Scope and Data Coverage
-
Global mRNA vaccines market analysis
-
Revenue forecasts to 2036
-
Segment-level modelling across vaccine type, application, and end user
-
Regional and national market forecasts
-
Competitive intelligence on 11 leading companies
Includes both quantitative forecasting and qualitative strategic analysis, covering technology, competition, policy, and supply chain dynamics.
Segmentation Framework
By Type
-
Self-amplifying mRNA-based Vaccines
-
Conventional Non-amplifying mRNA-based Vaccines
By Application
-
Cancer
-
Infectious Disease
-
Autoimmune Diseases
-
Others
By End User
-
Hospitals and Clinics
-
Research Organisations
-
Others
Geographic Coverage
North America
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Rest of Europe
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
South Korea
-
Rest of Asia Pacific
Latin America
-
Brazil
-
Mexico
-
Rest of Latin America
MEA
-
GCC
-
South Africa
-
Rest of MEA
Company Intelligence Coverage
This report includes detailed profiles of 11 leading companies, including:
-
AIM Vaccine
-
Arcturus Therapeutics, Inc.
-
BioNTech SE
-
DAIICHI SANKYO COMPANY, LIMITED
-
etherna
-
Ethris
-
GSK plc
-
Moderna, Inc.
-
Pfizer Inc.
-
Sanofi
-
Strand Therapeutics
Each profile includes:
-
Business overview
-
Financial and market positioning
-
Product and technology capabilities
-
Strategic outlook
Bespoke Intelligence & Customisation
Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements.
This includes:
-
Custom market segmentation and forecasts
-
Competitive benchmarking and strategy analysis
-
Policy and regulatory impact assessment
-
Supply chain and sourcing intelligence
-
Scenario modelling including tariffs and geopolitical risk
Why This Market Intelligence Matters
-
The mRNA vaccines market is evolving rapidly, driven by platform technology advances, expanding therapeutic applications, and shifting manufacturing and supply chain strategies.
-
Organisations that understand these dynamics will be better positioned to capture growth opportunities, manage risk, and strengthen competitive positioning.
-
Purchase the mRNA Vaccines Market Report 2026–2036 to access the complete dataset, forecasts, and competitive analysis.
ページTOPに戻る
Table of Contents
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to mRNA Vaccines Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Growing R&D Investments for Developing mRNA-based Vaccines
3.3.1.2 Technological Advancements in Delivery Systems
3.3.1.3 Increasing Government Initiatives and Policies to Promote Vaccination
3.3.2 Market Restraining Factors
3.3.2.1 High Price Association with mRNA Vaccine
3.3.2.2 Stringent Regulations for Approval of mRNA Vaccine
3.3.3 Market Opportunities
3.3.3.1 Expanding Applications of mRNA Vaccine
3.3.3.2 Growth of Localised mRNA Manufacturing & Tech Transfer Hubs
3.3.3.3 Advancements in Self-amplifying mRNA (saRNA) Platforms
3.4 U.S. Tariffs: What’s the Impact on Global mRNA Vaccines Market?
3.4.1 Overview
3.4.2 V-Shaped Recovery Scenario
3.4.3 Why V-Shaped Recovery?
3.4.3.1 Impact from Tariffs
3.4.3.2 Market Dynamics and Demand Recovery
3.4.3.3 Policy and Funding Support
3.4.3.4 Timeframe for Recovery
3.4.4 U-Shaped Recovery Scenario
3.4.4.1 Why U-Shaped Recovery?
3.4.4.2 Impact from Tariffs
3.4.4.3 Market Dynamics and Demand Recovery
3.4.4.4 Policy and Funding Support
3.4.4.5 Timeframe for Recovery
3.4.5 L Shaped Recovery Scenario
3.4.5.1 Why L-Shaped Recovery?
3.4.5.2 Impact from Tariffs
3.4.5.3 Market Dynamics and Demand Recovery
3.4.5.4 Policy and Funding Support
3.4.5.5 Timeframe for Recovery
3.4.6 What Strategic Considerations Should Clients Factor into Their Near-term (2026–2031) and Long-term (2026–2036) Planning?
3.4.7 Impact of U.S. and China Trade War on mRNA Vaccines Market
3.4.8 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
3.5 Porter’s Five Forces Analysis
3.5.1 Bargaining Power of Suppliers – Moderate to High
3.5.2 Bargaining Power of Buyers – Moderate
3.5.3 Competitive Rivalry – High
3.5.4 Threat of Substitutes – Moderate
3.5.5 Threat of New Entrants – Low
3.6 PEST Analysis
4 mRNA Vaccines Market Analysis by Type
4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 mRNA Vaccines Market Size Estimation and Forecast by Type
4.4 Self-amplifying mRNA-based Vaccines
4.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
4.4.2 Market Share by Region, 2026 & 2036 (%)
4.5 Conventional Non-amplifying mRNA-based Vaccines
4.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
4.5.2 Market Share by Region, 2026 & 2036 (%)
5 mRNA Vaccines Market Analysis by Application
5.1 Key Findings
5.2 Application Segment: Market Attractiveness Index
5.3 mRNA Vaccines Market Size Estimation and Forecast by Application
5.4 Cancer
5.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
5.4.2 Market Share by Region, 2026 & 2036 (%)
5.5 Infectious Disease
5.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
5.5.2 Market Share by Region, 2026 & 2036 (%)
5.6 Autoimmune Diseases
5.6.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
5.6.2 Market Share by Region, 2026 & 2036 (%)
5.7 Others
5.7.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
5.7.2 Market Share by Region, 2026 & 2036 (%)
6 mRNA Vaccines Market Analysis by End-users
6.1 Key Findings
6.2 End-users Segment: Market Attractiveness Index
6.3 mRNA Vaccines Market Size Estimation and Forecast by End-users
6.4 Hospitals and Clinics
6.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
6.4.2 Market Share by Region, 2026 & 2036 (%)
6.5 Research Organisations
6.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
6.5.2 Market Share by Region, 2026 & 2036 (%)
6.6 Others
6.6.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
6.6.2 Market Share by Region, 2026 & 2036 (%)
7 mRNA Vaccines Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast
8 North America mRNA Vaccines Market Analysis
8.1 Key Findings
8.2 North America mRNA Vaccines Market Attractiveness Index
8.3 North America mRNA Vaccines Market by Country, 2026, 2031 & 2036 (US$ Million)
8.4 North America mRNA Vaccines Market Size Estimation and Forecast by Country
8.5 North America mRNA Vaccines Market Size Estimation and Forecast by Type
8.6 North America mRNA Vaccines Market Size Estimation and Forecast by Application
8.7 North America mRNA Vaccines Market Size Estimation and Forecast by End-users
8.8 U.S. mRNA Vaccines Market Analysis
8.9 Canada mRNA Vaccines Market Analysis
9 Europe mRNA Vaccines Market Analysis
9.1 Key Findings
9.2 Europe mRNA Vaccines Market Attractiveness Index
9.3 Europe mRNA Vaccines Market by Country, 2026, 2031 & 2036 (US$ Million)
9.4 Europe mRNA Vaccines Market Size Estimation and Forecast by Country
9.5 Europe mRNA Vaccines Market Size Estimation and Forecast by Type
9.6 Europe mRNA Vaccines Market Size Estimation and Forecast by Application
9.7 Europe mRNA Vaccines Market Size Estimation and Forecast by End-users
9.8 Germany mRNA Vaccines Market Analysis
9.9 UK mRNA Vaccines Market Analysis
9.10 France mRNA Vaccines Market Analysis
9.11 Italy mRNA Vaccines Market Analysis
9.12 Spain mRNA Vaccines Market Analysis
9.13 Rest of Europe mRNA Vaccines Market Analysis
10 Asia Pacific mRNA Vaccines Market Analysis
10.1 Key Findings
10.2 Asia Pacific mRNA Vaccines Market Attractiveness Index
10.3 Asia Pacific mRNA Vaccines Market by Country, 2026, 2031 & 2036 (US$ Million)
10.4 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by Country
10.5 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by Type
10.6 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by Application
10.7 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by End-users
10.8 Japan mRNA Vaccines Market Analysis
10.9 China mRNA Vaccines Market Analysis
10.10 India mRNA Vaccines Market Analysis
10.11 Australia mRNA Vaccines Market Analysis
10.12 Rest of Asia Pacific mRNA Vaccines Market Analysis
11 Latin America mRNA Vaccines Market Analysis
11.1 Key Findings
11.2 Latin America mRNA Vaccines Market Attractiveness Index
11.3 Latin America mRNA Vaccines Market by Country, 2026, 2031 & 2036 (US$ Million)
11.4 Latin America mRNA Vaccines Market Size Estimation and Forecast by Country
11.5 Latin America mRNA Vaccines Market Size Estimation and Forecast by Type
11.6 Latin America mRNA Vaccines Market Size Estimation and Forecast by Application
11.7 Latin America mRNA Vaccines Market Size Estimation and Forecast by End-users
11.8 Brazil mRNA Vaccines Market Analysis
11.9 Mexico mRNA Vaccines Market Analysis
11.10 Rest of Latin America mRNA Vaccines Market Analysis
12 MEA mRNA Vaccines Market Analysis
12.1 Key Findings
12.2 MEA mRNA Vaccines Market Attractiveness Index
12.3 MEA mRNA Vaccines Market by Country, 2026, 2031 & 2036 (US$ Million)
12.4 MEA mRNA Vaccines Market Size Estimation and Forecast by Country
12.5 MEA mRNA Vaccines Market Size Estimation and Forecast by Type
12.6 MEA mRNA Vaccines Market Size Estimation and Forecast by Application
12.7 MEA mRNA Vaccines Market Size Estimation and Forecast by End-users
12.8 GCC mRNA Vaccines Market Analysis
12.9 South Africa mRNA Vaccines Market Analysis
12.10 Rest of MEA mRNA Vaccines Market Analysis
13 Company Profiles
13.1 Pfizer Inc.
13.1.1 Company Snapshot
13.1.2 Company Overview
13.1.3 Financial Analysis
13.1.3.1 Net Revenue, 2021-2025
13.1.3.2 R&D, 2021-2025
13.1.3.3 Regional Market Shares, 2025
13.1.3.4 Business Segment Market Shares, 2025
13.1.4 Product Benchmarking
13.1.5 Strategic Outlook
13.2 Moderna, Inc.
13.2.1 Company Snapshot
13.2.2 Company Overview
13.2.3 Financial Analysis
13.2.3.1 Net Revenue, 2021-2025
13.2.3.2 R&D, 2021-2025
13.2.3.3 Regional Market Shares, 2025
13.2.3.4 Business Segment Market Shares, 2025
13.2.4 Product Benchmarking
13.2.5 Strategic Outlook
13.3 BioNTech SE
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.3.1 Net Revenue, 2021-2025
13.3.3.2 R&D, 2021-2025
13.3.3.3 Regional Market Shares, 2025
13.3.3.4 Business Segment Market Shares, 2025
13.3.4 Product Benchmarking
13.3.5 Strategic Outlook
13.4 GSK plc
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Analysis
13.4.3.1 Net Revenue, 2021-2025
13.4.3.2 R&D, 2021-2025
13.4.3.3 Regional Market Shares, 2025
13.4.3.4 Business Segment Market Shares, 2025
13.4.4 Product Benchmarking
13.4.5 Strategic Outlook
13.5 DAIICHI SANKYO COMPANY, LIMITED
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis
13.5.3.1 Net Revenue, 2021-2025
13.5.3.2 R&D, 2021-2025
13.5.3.3 Regional Market Shares, 2025
13.5.4 Product Benchmarking
13.6 Ethris
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Product Benchmarking
13.6.4 Strategic Outlook
13.7 AIM Vaccine
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.3.1 Net Revenue, 2022-2024
13.7.4 Product Benchmarking
13.7.5 Strategic Outlook
13.8 Arcturus Therapeutics, Inc.
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Product Benchmarking
13.8.4 Strategic Outlook
13.9 Sanofi
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis
13.9.3.1 Net Revenue, 2021-2025
13.9.3.2 R&D, 2021-2025
13.9.3.3 Regional Market Shares, 2025
13.9.3.4 Business Segment Market Shares, 2025
13.9.4 Product Benchmarking
13.9.5 Strategic Outlook
14 Conclusion and Recommendations
14.1 Concluding Remarks from Visiongain
14.2 Recommendations for Market Players
ページTOPに戻る
List of Tables/Graphs
List of Tables
Table 1 mRNA Vaccines Market Snapshot, 2026 & 2036 (US$ million, CAGR %)
Table 2 mRNA Vaccines Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%): “V” Shaped Recovery
Table 3 mRNA Vaccines Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%): “U” Shaped Recovery
Table 4 mRNA Vaccines Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%): “L” Shaped Recovery
Table 5 mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 6 Self-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 7 Conventional Non-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 8 mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 9 Cancer Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 10 Infectious Diseases Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 11 Autoimmune DiseasesSegment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 12 Other Applications Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 13 mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 14 Hospitals and Clinics Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 15 Research Organisations Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 16 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 17 mRNA Vaccines Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 18 North America mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 19 North America mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 20 North America mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 21 North America mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 22 U.S. mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 23 Canada mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 24 Europe mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 25 Europe mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 26 Europe mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 27 Europe mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 28 Germany mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 29 UK mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 30 France mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 31 Italy mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 32 Spain mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 33 Rest of Europe mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 34 Asia Pacific mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 35 Asia Pacific mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 36 Asia Pacific mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 37 Asia Pacific mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 38 Japan mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 39 China mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 40 India mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 41 Australia mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 42 Rest of Asia Pacific mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 43 Latin America mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 44 Latin America mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 45 Latin America mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 46 Latin America mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 47 Brazil mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 48 Mexico mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 49 Rest of Latin America mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 50 MEA mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 51 MEA mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 52 MEA mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 53 MEA mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
Table 54 GCC mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 55 South Africa mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 56 Rest of MEA mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
Table 57 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 58 Pfizer Inc.: Product Benchmarking
Table 59 Pfizer Inc.: Strategic Outlook
Table 60 Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 61 Moderna, Inc.: Product Benchmarking
Table 62 Moderna, Inc.: Strategic Outlook
Table 63 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 64 BioNTech SE: Product Benchmarking
Table 65 BioNTech SE: Strategic Outlook
Table 66 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 67 GSK plc: Product Benchmarking
Table 68 GSK plc: Strategic Outlook
Table 69 DAIICHI SANKYO COMPANY, LIMITED: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 DAIICHI SANKYO COMPANY, LIMITED: Product Benchmarking
Table 71 Ethris: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 72 Ethris: Product Benchmarking
Table 73 Ethris: Strategic Outlook
Table 74 AIM Vaccine: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 75 AIM Vaccine: Product Benchmarking
Table 76 AIM Vaccine: Strategic Outlook
Table 77 Arcturus Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 78 Arcturus Therapeutics, Inc.: Product Benchmarking
Table 79 Arcturus Therapeutics, Inc.: Strategic Outlook
Table 80 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Sanofi: Product Benchmarking
Table 82 Sanofi: Strategic Outlook
List of Figures
Figure 1 mRNA Vaccines Market Segmentation
Figure 2 mRNA Vaccines Market by Type: Market Attractiveness Index
Figure 3 mRNA Vaccines Market by Application: Market Attractiveness Index
Figure 4 mRNA Vaccines Market by End-users: Market Attractiveness Index
Figure 5 mRNA Vaccines Market Attractiveness Index by Region
Figure 6 mRNA Vaccines Market: Market Dynamics
Figure 7 mRNA Vaccines Market: Impact Analysis
Figure 8 mRNA Vaccines Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 9 mRNA Vaccines Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 10 mRNA Vaccines Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 11 Short Term & Long Term Planning
Figure 12 Impact of U.S. and China Trade War
Figure 13 Most Impacted Countries
Figure 14 mRNA Vaccines Market: Porter’s Five Forces Analysis
Figure 15 mRNA Vaccines Market: PEST Analysis
Figure 16 mRNA Vaccines Market Attractiveness Index by Type
Figure 17 mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
Figure 18 mRNA Vaccines Market Share Forecast by Type, 2026, 2031, 2036 (%)
Figure 19 Self-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 20 Self-amplifying mRNA-based Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 21 Conventional Non-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 22 Conventional Non-amplifying mRNA-based Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 23 mRNA Vaccines Market Attractiveness Index by Type
Figure 24 mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
Figure 25 mRNA Vaccines Market Share Forecast by Application, 2026, 2031, 2036 (%)
Figure 26 Cancer Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 27 Cancer Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 28 Infectious Disease Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 29 Infectious Disease Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 30 Autoimmune Diseases Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 31 Autoimmune Diseases Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 32 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 33 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 34 mRNA Vaccines Market Attractiveness Index by End-users
Figure 35 mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
Figure 36 mRNA Vaccines Market Share Forecast by End-users, 2026, 2031, 2036 (%)
Figure 37 Hospitals and Clinics Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 38 Hospitals and Clinics Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 39 Research Organisations Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 40 Research Organisations Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 41 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 42 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 43 mRNA Vaccines Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
Figure 44 mRNA Vaccines Market Share Forecast by Region 2026, 2031, 2036 (%)
Figure 45 mRNA Vaccines Market by Region, 2026-2036 (US$ Mn)
Figure 46 North America mRNA Vaccines Market Attractiveness Index
Figure 47 North America mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 48 North America mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 49 North America mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
Figure 50 North America mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
Figure 51 North America mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
Figure 52 North America mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
Figure 53 North America mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
Figure 54 North America mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
Figure 55 North America mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 56 U.S. mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 57 Canada mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 58 Europe mRNA Vaccines Market Attractiveness Index
Figure 59 Europe mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 60 Europe mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 61 Europe mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
Figure 62 Europe mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
Figure 63 Europe mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
Figure 64 Europe mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
Figure 65 Europe mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
Figure 66 Europe mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
Figure 67 Europe mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 68 Germany mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 69 UK mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 70 France mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 71 Italy mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 72 Spain mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 73 Rest of Europe mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 74 Asia Pacific mRNA Vaccines Market Attractiveness Index
Figure 75 Asia Pacific mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 76 Asia Pacific mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 77 Asia Pacific mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
Figure 78 Asia Pacific mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
Figure 79 Asia Pacific mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
Figure 80 Asia Pacific mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
Figure 81 Asia Pacific mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
Figure 82 Asia Pacific mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
Figure 83 Asia Pacific mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 84 Japan mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 85 China mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 86 India mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 87 Australia mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 88 Rest of Asia Pacific mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 89 Latin America mRNA Vaccines Market Attractiveness Index
Figure 90 Latin America mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 91 Latin America mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 92 Latin America mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
Figure 93 Latin America mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
Figure 94 Latin America mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
Figure 95 Latin America mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
Figure 96 Latin America mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
Figure 97 Latin America mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
Figure 98 Latin America mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 99 Brazil mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 100 Mexico mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 101 Rest of Latin America mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 102 MEA mRNA Vaccines Market Attractiveness Index
Figure 103 MEA mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 104 MEA mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 105 MEA mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
Figure 106 MEA mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
Figure 107 MEA mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
Figure 108 MEA mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
Figure 109 MEA mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
Figure 110 MEA mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
Figure 111 MEA mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
Figure 112 GCC mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 113 South Africa mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 114 Rest of MEA mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 115 Pfizer Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 116 Pfizer Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 117 Pfizer Inc.: Regional Market Shares (%), 2025
Figure 118 Pfizer Inc.: Business Segment Market Shares (%), 2025
Figure 119 Moderna, Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 120 Moderna, Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 121 Moderna, Inc.: Regional Market Shares (%), 2025
Figure 122 Moderna, Inc.: Business Segment Market Shares (%), 2025
Figure 123 BioNTech SE: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 124 BioNTech SE: R&D, 2021-2025 (US$ Million, AGR %)
Figure 125 BioNTech SE: Regional Market Shares (%), 2025
Figure 126 BioNTech SE: Business Segment Market Shares (%), 2025
Figure 127 GSK plc: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 128 GSK plc: R&D, 2021-2025 (US$ Million, AGR %)
Figure 129 GSK plc: Regional Market Shares (%), 2025
Figure 130 GSK plc: Business Segment Market Shares (%), 2025
Figure 131 DAIICHI SANKYO COMPANY, LIMITED: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 132 DAIICHI SANKYO COMPANY, LIMITED: R&D, 2021-2025 (US$ Million, AGR %)
Figure 133 DAIICHI SANKYO COMPANY, LIMITED: Regional Market Shares (%), 2025
Figure 134 AIM Vaccine: Net Revenue, 2022-2024 (US$ Million, AGR %)
Figure 135 Sanofi: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 136 Sanofi: R&D, 2021-2025 (US$ Million, AGR %)
Figure 137 Sanofi: Regional Market Shares (%), 2025
Figure 138 Sanofi: Business Segment Market Shares (%), 2025
ページTOPに戻る
- 世界の環境DNA市場 2026-2030年
- 世界の精密診断市場 2026-2030年
- siRNA Chemical, Linkers And Reagents Market Size, Share & Trends Analysis Report By Type (siRNA Synthesis Chemicals, Chemical Modifiers, Linkers, Conjugation Reagents), By Application (Research & Discovery, Drug Delivery Platform Development), By End-use, By Region, And Segment Forecasts, 2026 - 2033
- Proteomics Market Size, Share & Trends Analysis Report By Product & Service (Instruments, Reagents & Consumables, Services), By Application (Drug Discovery, Clinical Diagnostics), By Technology (Spectrometry, Chromatography), By Region, And Segment Forecasts, 2026 - 2033
- Life Science Tools Market Size, Share & Trends Analysis Report By Technology (Cell Biology, Proteomics), By Product & Service (Cell Culture Systems & 3D Cell Culture, Liquid Chromatography), By End-use (Government & Academic, Healthcare), By Region, And Segment Forecasts, 2026 - 2033
- DNA Sequencing Market Size, Share & Trends Analysis Report By Product & Service (Instruments, Consumables, Services), By Technology (Sanger Sequencing, Next-Generation Sequencing), By Workflow (Pre-sequencing, Sequencing), By Application, By End-use, And Segment Forecasts, 2026 - 2033
- Cell Signaling Market Size, Share & Trends Analysis Report By Type (Endocrine Signaling, Paracrine Signaling), By Product (Consumables, Instruments), By Technology (Flow Cytometry, Microscopy), By Pathway, By Region, And Segment Forecasts, 2026 - 2033
- Aptamers Market Size, Share & Trends Analysis Report By Type (Nucleic Acid Aptamer, Peptide Aptamer), By Application (Diagnostics, Therapeutics Development, Research & Development), By Region, And Segment Forecasts, 2026 - 2033
- Preparative And Process Chromatography Market Size, Share & Trends Analysis Report By Product (Process Chromatography, Preparative Chromatography), By Type (Liquid Chromatography, Gas Chromatography), By End Use, By Region, And Segment Forecasts, 2026 - 2033
- Epigenetics Market by Product, Service, Method, Technique, Application - Global Forecast to 2031
よくあるご質問
Visiongain社はどのような調査会社ですか?
英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る
調査レポートの納品までの日数はどの程度ですか?
在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。
注文の手続きはどのようになっていますか?
1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。
お支払方法の方法はどのようになっていますか?
納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。
データリソース社はどのような会社ですか?
当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。
|
|
